80eefb9a-ab84-11e6-9cb3-bb8207902122
By David Crow

High stakes: Eli Lilly’s hunt for an Alzheimer’s drug

On Wednesday, the pharma giant learnt that Sola — a drug it hoped would slow the progression of the disease — had failed its phase III trial. Before that, David Crow reported on the company’s long search for a cure

On Wednesday, the pharma giant learnt that Sola — a drug it hoped would slow the progression of the disease — had failed its phase III trial. Before that, David Crow reported on the company’s long search for a cure